These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. The emerging role for type 5 phosphodiesterase inhibition in heart failure. Lewis GD; Semigran MJ Curr Heart Fail Rep; 2006 Sep; 3(3):123-8. PubMed ID: 16914104 [TBL] [Abstract][Full Text] [Related]
6. Oxidative stress regulates left ventricular PDE5 expression in the failing heart. Lu Z; Xu X; Hu X; Lee S; Traverse JH; Zhu G; Fassett J; Tao Y; Zhang P; dos Remedios C; Pritzker M; Hall JL; Garry DJ; Chen Y Circulation; 2010 Apr; 121(13):1474-83. PubMed ID: 20308615 [TBL] [Abstract][Full Text] [Related]
7. Acute phosphodiesterase 5 inhibition mimics hemodynamic effects of B-type natriuretic peptide and potentiates B-type natriuretic peptide effects in failing but not normal canine heart. Forfia PR; Lee M; Tunin RS; Mahmud M; Champion HC; Kass DA J Am Coll Cardiol; 2007 Mar; 49(10):1079-88. PubMed ID: 17349888 [TBL] [Abstract][Full Text] [Related]
8. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Wallis RM; Corbin JD; Francis SH; Ellis P Am J Cardiol; 1999 Mar; 83(5A):3C-12C. PubMed ID: 10078537 [TBL] [Abstract][Full Text] [Related]
9. Phosphodiesterase 5 and effects of sildenafil on cerebral arteries of man and guinea pig. Kruuse C; Khurana TS; Rybalkin SD; Birk S; Engel U; Edvinsson L; Olesen J Eur J Pharmacol; 2005 Oct; 521(1-3):105-14. PubMed ID: 16182282 [TBL] [Abstract][Full Text] [Related]
10. Postnatal maturation of phosphodiesterase 5 (PDE5) in piglet pulmonary arteries: activity, expression, effects of PDE5 inhibitors, and role of the nitric oxide/cyclic GMP pathway. Moreno L; Losada B; Cogolludo Al; Lodi F; Lugnier C; Villamor E; Moro M; Tamargo J; Pérez-Vizcaíno F Pediatr Res; 2004 Oct; 56(4):563-70. PubMed ID: 15295092 [TBL] [Abstract][Full Text] [Related]
11. Effect of sildenafil on cyclic nucleotide phosphodiesterase activity, vascular tone and calcium signaling in rat pulmonary artery. Pauvert O; Lugnier C; Keravis T; Marthan R; Rousseau E; Savineau JP Br J Pharmacol; 2003 Jun; 139(3):513-22. PubMed ID: 12788811 [TBL] [Abstract][Full Text] [Related]
12. Maximizing the renal cyclic 3'-5'-guanosine monophosphate system with type V phosphodiesterase inhibition and exogenous natriuretic peptide: a novel strategy to improve renal function in experimental overt heart failure. Chen HH; Huntley BK; Schirger JA; Cataliotti A; Burnett JC J Am Soc Nephrol; 2006 Oct; 17(10):2742-7. PubMed ID: 16928803 [TBL] [Abstract][Full Text] [Related]
13. Type 5 phosphodiesterase inhibition in heart failure and pulmonary hypertension. Lewis GD; Semigran MJ Curr Heart Fail Rep; 2004 Dec; 1(4):183-9. PubMed ID: 16036043 [TBL] [Abstract][Full Text] [Related]
14. Differential effects of the phosphodiesterase type 5 inhibitors sildenafil, vardenafil, and tadalafil in rat aorta. Teixeira CE; Priviero FB; Webb RC J Pharmacol Exp Ther; 2006 Feb; 316(2):654-61. PubMed ID: 16204472 [TBL] [Abstract][Full Text] [Related]
15. NADPH oxidase contributes to coronary endothelial dysfunction in the failing heart. Zhang P; Hou M; Li Y; Xu X; Barsoum M; Chen Y; Bache RJ Am J Physiol Heart Circ Physiol; 2009 Mar; 296(3):H840-6. PubMed ID: 19168727 [TBL] [Abstract][Full Text] [Related]
16. Cardiac electrophysiologic and hemodynamic effects of sildenafil, a PDE5 inhibitor, in anesthetized dogs. Sugiyama A; Satoh Y; Shiina H; Takahara A; Yoneyama M; Hashimoto K J Cardiovasc Pharmacol; 2001 Dec; 38(6):940-6. PubMed ID: 11707698 [TBL] [Abstract][Full Text] [Related]
17. Cyclic GMP phosphodiesterase-5: target of sildenafil. Corbin JD; Francis SH J Biol Chem; 1999 May; 274(20):13729-32. PubMed ID: 10318772 [No Abstract] [Full Text] [Related]
18. Overall cardiovascular profile of sildenafil citrate. Zusman RM; Morales A; Glasser DB; Osterloh IH Am J Cardiol; 1999 Mar; 83(5A):35C-44C. PubMed ID: 10078541 [TBL] [Abstract][Full Text] [Related]
19. cGMP-hydrolytic activity and its inhibition by sildenafil in normal and failing human and mouse myocardium. Vandeput F; Krall J; Ockaili R; Salloum FN; Florio V; Corbin JD; Francis SH; Kukreja RC; Movsesian MA J Pharmacol Exp Ther; 2009 Sep; 330(3):884-91. PubMed ID: 19546307 [TBL] [Abstract][Full Text] [Related]
20. Sildenafil in patients with cardiovascular disease. Brindis RG; Kloner RA Am J Cardiol; 2003 Nov; 92(9A):26M-36M. PubMed ID: 14609621 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]